Skip to content
Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA

News -

Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA

Recent news highlights that the Factor XI inhibitor space is emerging as the next significant advancement in cardiovascular care, and at Ribo, we are proud to be at the forefront of this development.

FXI inhibition has the potential to address a substantial unmet need and to represent a breakthrough in anti-coagulation therapy for millions of patients who are currently not receiving adequate treatment. Our siRNA approach for FXI inhibition offers a long duration of action compared to other modalities, such as antibodies, and allows for rapid reversibility if needed.

Our Phase 2 program is progressing well and according to plan. Ribo’s siRNA asset, RBD4059, is poised to offer a truly differentiated therapy in this space.

Related links

Topics

Categories

Contacts

  • Blood vessel_AI_Copilot Feb 2025 16_9.png
    Blood vessel_AI_Copilot Feb 2025 16_9.png
    License:
    All rights reserved
    File format:
    .png
    Size:
    1024 x 576, 1.13 MB